Crinetics Doses First Patient in BALANCE-CAH Trial
Crinetics announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia in children and adolescents.
